Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

JERUSALEM, & LUND, Sweden--(BUSINESS WIRE)--May 1, 2007 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated. In addition, there was a favorable trend towards reducing annual relapse rates, the number of relapse-free patients and time to first relapse compared with placebo. Treatment with a 0.3 mg dose showed no statistical significant difference compared with placebo.

These data were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007.

"Current RRMS options are effective for the treatment of the disease, but an oral therapy such as laquinimod would represent a milestone for patients as it would provide them with a completely unique, non-invasive method of drug delivery," said Giancarlo Comi, M.D., Director of Department of Neurology and Institute of Experimental Neurology, Universita Vita-Salute, San Raffaele, Milan, Italy. "Preliminary studies have already demonstrated the positive effect of laquinimod versus placebo, but these new data confirmed that a higher dose was even more effective and remained well tolerated."

The 36-week study evaluated the effect of oral daily 0.3 and 0.6 mg doses of laquinimod on MRI-monitored disease activity in patients with RRMS. The majority of the patients who participated in the study continued treatment with laquinimod in an ongoing, blinded 9 month extension study. This extension study is followed by an open label study where patients will receive 0.6 mg laquinimod for an additional 24 months.

"The results of this study, which once again demonstrate the efficacy and tolerability of once-dai
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:12/19/2014)... Dec. 19, 2014  Monarch America Inc. (OTCQB: CANK) ... is pleased to provide this review of the Company,s ... 2015. "Over this past year, we achieved ... am extremely proud to say that Monarch America is ... it has ever been," stated Eric Hagen , ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ( ... of equipment for the testing of marijuana potency ... the new Luminary™ Profiler, the industry,s first product ... in a cost-effective, portable unit. Designed ... needs of the cannabis industry, the Luminary™ Profiler ...
(Date:12/19/2014)... WASHINGTON , Dec. 18, 2014 Since ... Road, the site now known as the leading online ... has seen explosive growth in its offering of drugs ... Citizens Alliance show the takedowns did succeed in lowering ... our last review of the markets in August. But ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3
... 16, 2011 Reportlinker.com announces that ... available in its catalogue: ... and Peptides ... analysis focuses on cancer drug development ...
... 16, 2011 Unilife Corporation (NASDAQ: UNIS ... pricing of its underwritten registered public offering of 8,250,000 shares ... per share. All of the shares in the offering are ... the Company also granted the underwriters a 30-day option to ...
Cached Medicine Technology:Triple Analysis: Leukemia, Cancer Vaccines and Peptides 2Triple Analysis: Leukemia, Cancer Vaccines and Peptides 3Triple Analysis: Leukemia, Cancer Vaccines and Peptides 4Triple Analysis: Leukemia, Cancer Vaccines and Peptides 5Unilife Corporation Announces Pricing of Offering of 8,250,000 Shares of Common Stock 2Unilife Corporation Announces Pricing of Offering of 8,250,000 Shares of Common Stock 3
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Estes Park, Colo. The top executive ... has recently placed more than 900 healthcare executives into ... a 25-bed, not-for-profit critical access hospital and level IV ...
(Date:12/19/2014)... Hands On Mobile Spa, has announced they ... On Wheels has been transformed into a utopia for the ... seems to disappear. The Virtual Tour showcases the beauty of ... corporate events and more. , The Virtual Tour shows viewers ... is actually an overhauled Winnebago. Marla Kaplan-Pelle, Director states " ...
(Date:12/19/2014)... Slone Partners , a national recruitment firm ... and laboratory testing industries, has promoted Leslie Loveless ... announcement comes after a year of expansion by ... Boston and several new additions to the team. ... experience," said Adam Slone, Chief Executive Officer. “Diagnostics ...
(Date:12/19/2014)... 2014 The Hermitage Club at ... Southern Vermont’s Deerfield Valley, announced today that it has ... rock songs. , Three time Grammy Award Winner ... concert followed by a trail naming ceremony. Hermitage Club ... include: “I’m Alright” the theme song for the movie ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... high levels of air pollution late in pregnancy may have ... Researchers found that of nearly 1,800 U.S. women who ... most air pollution during pregnancy were twice as likely to ... the third trimester, specifically, showed the strongest correlation to autism ...
Breaking Medicine News(10 mins):Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... WASHINGTON, Feb. 1 The American Public,Health Association (APHA) ... of Congress voted on legislation that is,important to public ... of individual votes,and selecting key public health votes during ... In the Senate, 46 out of 100 senators voted ...
... the vital role wetlands play in society, they remain among ... and positive effects of healthy wetlands for humans, the theme ... 2 February, is Healthy Wetlands, Healthy People. , According to ... claims the lives of more than 3 million people every ...
... Clinton,Campaign today announced the endorsement of the American ... the nation,s 2.9 million,registered nurses., "Too many ... and this,country deserves a president that will make ... M. Patton, MSN, RN, CNOR. "Senator,Clinton has shown ...
... 1 The Beaumont Technology,Usability Center will begin ... Food and,Drug Administration,s study on tubing and catheter ... released a Sentinel Event Alert on the,potential dangers ... and one instance of permanent loss of function ...
... Corporation (Nasdaq: OSCI ) will release financial ... December 31, 2007 on,Wednesday, February 6, 2008 prior ... conference call will be held at 8:30 a.m. ... other members of Oscient,s,management team. The Company announced ...
... of Acne ... Treatment, ... MD and co-investigators Mikiko,Enokibori, MD, and Vic Narurkar, MD, conducted a ... of acne,ranging from mild and moderate inflammatory acne to severe nodular ...
Cached Medicine News:Health News:APHA Scores Members of Congress on Public Health Voting Record 2Health News:Connection between health of wetlands and humans in focus 2Health News:Connection between health of wetlands and humans in focus 3Health News:The American Nurses Association Endorses Senator Hillary Rodham Clinton (D-NY) 2Health News:FDA Renews its Contract with Beaumont Technology Usability Center for Leadership of Patient Safety Project 2Health News:Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results 2Health News:New Study Shows Isolaz Can Reduce Acne Up to 90 Percent 2Health News:New Study Shows Isolaz Can Reduce Acne Up to 90 Percent 3
... Constructed of optical steel ... electro-plate. Comes with custom ... that create a seal ... for increased scatter radiation ...
... steel base metal with bronze ... custom fitted 0.50mm leaded side ... to the front lenses for ... exposure. Includes adjustable non-slip silicon ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... eye protection Properly manufactured radiation protective ... radiation. Our high quality frames and materials ... minimized weight. Our lenses are made of ... all industry standards. Most Pulse Glasses are ...
Medicine Products: